Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services
Executive Summary
Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.
You may also be interested in...
Silicon Valley Bank’s Failure Rattles Investors In Biopharma Sector
Investment bank analysts, VC funds and biopharma companies all sought to calm investors’ nerves as a go-to financial institution for tech and biotech collapsed.
Enavate Launches With $300m To Help Drug Developers Get Over Funding Hurdles
The firm, helmed by former life science investment banker James Boylan, views the current difficult financial market as the perfect time to offer its expertise and capital to growing companies.
InCarda Gets $30m Closer To Inhalable AF Drug/Device Therapy
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.